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      Bacterial meningitis in neonates and children in South Africa 
   A: Introduction 
 
1. The problem: 







. In South Africa fatality rates among infants and 




Acute bacterial meningitis is defined as the inflammation of the meninges. It is 
caused by various bacteria and the specific aetiology is age dependant
iv
. In the 
neonatal period the causative organisms are: Group B streptococci, Gram - 





. In infants and children up to the age of 5 the most 
common causative organisms include: Streptococcus pneumoniae, Haemophilus 
influenzae type B  (Hib)and Neiseria meningitidis
iv, v
. The two chief causes of 





Various studies have been performed to look at the profile of meningitis among 
the paediatric population
i, vi, ii
.   
A study looking at bacterial meningitis among Cape metro pole children from 
1991 to 1992 found that N. Meningitidis was the most common causative 
organism of bacterial meningitis in this study’s setting
vii
. This was followed by H. 
influenzae and S. Pneumoniae respectively
vii 
.The average age of children  in this 
study with Haemophillus and Pneumococcal meningitis were similar at 9  and 7,5 











average of 22 months
vii 
.Two earlier studies conducted in the Western Cape also 
found that N. Mengitidis was the most common causative organism of childhood 




A 2-year retrospective study of the 
epidemiology of bacterial meningitis was conducted in Johannesburg from 1980 –
1982
x
.This study looked at the aetiology, age distribution, seasonal variation and 





Meningitidis was the organism most frequently isolated, followed by S. 





trends were noted: Meningococcal and Pneumococcal meningitis occurred more 
frequently in spring and winter, while there was no seasonal peak for 
Haemophillus meningitis
x 
. Most of the cases of Haemophillus meningitis were 




A surveillance of bacterial meningitis in 
Mozambique found that H. influenzae b was the most common causative organism 








With the advent of preventative strategies, most notably the introduction of the 
Haemophilus type B vaccine and the pneumococcal conjugate vaccine, one would 
expect a changing pattern in the incidence of certain causative organisms
ii
. A 
study documenting the causative organisms of bacterial meningitis in Korean 
children from 1996 –2005 found that Haemophilus influenza meningitis had 















meningitis showed a reduction of Haemophilus b since the introduction of the H. 
influenza b vaccine
ii
. In developed countries, the routine use of the Haemophilus 
B vaccine has shown a reduction of 99% of invasive Haemophilus disease
iv
. The
vaccine has also reduced the Haemophilus B disease in developing countries
xii
South Africa was the first African country to finance the introduction of the
Haemophilus b vaccine into the vaccination schedule from July 1999
xii
There has 
been a significant decrease in the incidence of invasive Haemophilus b disease
following the introduction of the Haemophilus b vaccine into the vaccination 
schedule
xii
. The afore mentioned study in Mozambique concluded that more than 
40% of the bacterial meningitis cases were potentially preventable by the
Pneumococcal or Hib conjugate vaccines
xi
.
S. pneumoniae is a very important cause of meningitis amongst children and 
infants
i
.The conjugate Pneumococcal vaccine covers against seven of the
pneumococcus strains 
i
. Since the introduction of this vaccine in the USA the
incidence of S. pneumonia meningitis has declined by 30.1 %
i
. Despite this, S
pneumonia still remains the most common cause of bacterial meningitis in 
children in the USA
i
. This is due to the emergence of pnuemococcal strains not 
covered by the conjugate vaccine
i
.The seven valent Pneumococcal conjugate
vaccine was registered in South Africa in 2005 but only introduced as part of the
public sector immunisation schedule in April 2009. 
xii
Children born after 15
February 2009 were eligible for the Pnuemococcal conjugate vaccine and no catch 
up immunisation was planned
xii
.The use of the Pneumococcal and H. Influenza b 
















A retrospective study done at Tygerberg Hospital in the Western Cape looked at 
the following aspects of neonatal meningitis: mortality, CSF and microbiological 
findings
xiv
 .This study looked at the records of those treated for bacterial 
meningitis from July 1981 to June 1992
xiv
 .Eighty eight patients were included.  In 
this study the most common causative organism of neonatal meningitis was group 
B Streptococcus followed by E. coli and.  K pneumonia.
xiv 
 .In this study there was 
only one case of Listeria Monocytogenes, showing that Listeria is a rare cause of 




Amongst neonates, group B streptococci remain an important cause of 
meningitis
i,vi 
. Intrapartum antibiotics (penicillin or ampicillin) administered to 
women colonised rectally or vaginally with group B streptococci has shown to 
reduce early onset neonatal group B streptococcal sepsis
v 
.Intrapartum antibiotic 
prophylaxis does not, however, significantly decrease the rate of late onset group 
B streptococcal sepsis and, unfortunately, most cases of group B streptococcal 
meningitis occur later in the neonatal period
v  
.Immunisation of mothers with the 
group B streptococcal conjugate vaccine may be used as a future strategy to 
prevent neonatal group b streptococcal meningitis
iv
 .  
  
 
The Group for Enteric, Respiratory and Meningeal disease Surveillance in South 











diseases surveillance bulletin ( available on the National Institute for Communicable 
Diseases website.)   
GERMS –SA found that the overall incidence of N. Meningitidis remained the same 
in 2008 and 2009
xv
 .Five percent of N. Meningitidis isolates were intermediately 
resistant to penicillin
xv 
 .GERMS – SA still, therefore , recommends penicillin as the 
anti biotic of choice for confirmed meningococcal disease
xv  
.When looking at H. 
Influenzae, GERMS –SA  found that serotype b was the most common H. Influenzae 
causing illness in infants
xv
. in 2009 there was an increase in Hib disease in those 
under 1 year of age
xv
.It was found that 19% of Hib were resistant to ampicillin
xv
.The 
age group most at risk of contracting invasive pneumococcal disease was those under 
1 years old
xv 
.GERMS – SA did, however , find that there has been a decrease in 
invasive Pneumococcal disease in infants under 1 year . They attributed this to the 
introduction of the conjugate Pneumococcal vaccine in South Africa in 2009
xv 
.The 
GERMS –SA data for 2009 showed an increase in Pneumococcal resistance to 
penicillin and ceftriaxone
xv 
.GERMS –SA , however, believes that this increase is due 
to a change in laboratory methods introduced in 2009
xv 
 .It is therefore recommended 





















 2. Objective:  
To investigate the aetiology of acute bacterial meningitis in South African 
newborns and children from 2005 - 2010. 
 
- To determine the prevalence   (and 95 % confidence interval) of causative 
organisms of acute bacterial meningitis among culture positive cerebral spinal 
fluid (CSF) in four paediatric periods namely: 1. The neonatal period (day 0 – 28 
days of life); 2. 1 – 3 months; 3.  3 months to 5 years) and 4. Children older than 5 
years of age up till 12 years.  
 
3. Subsidiary Objectives: 
- To compare the prevalence (and 95% confidence interval) of the causative 
organisms among culture positive CSF between the various age groups. (The 
null hypothesis being: There is no difference in the causative organisms 
between the 4 age groups)   
- To determine the relative proportions (and 95% confidence interval) of 
pneumococcal meningitis prior to and after the introduction of the conjugate 
pneumococcal vaccine. (The null hypothesis being: There is no difference in 
the incidence of pneumococcal meningitis before and after the introduction of 
the conjugated pneumococcal vaccine.) 
- To determine antibiotic resistance and sensitivity patterns among the 














        B Methods:  
1. Study Design
       This will be a retrospective descriptive and analytical cross sectional study. 
2. Subject selection:
The subjects of this study will be patients in the paediatric population (age 0 –
12years) who have had a positive culture result on CSF from 2005 - 2010 in the
provinces, whose data, is captured on the Corporate Data Warehouse (CDW). This 
includes all South African provinces except for Kwazulu Natal.  The sample will 
represent the paediatric population who make use of the government hospitals in 
South Africa. The inclusion criteria will be the following: patients aged 0 –
12years; an organism was cultured on the subject’s CSF. Exclusion criteria will 
be:  meningitis which is not acute: i.e. mycobacterium tuberculosis, patients older




 A database will be created in excel onto which the various variables will be captured. 
The variables will be listed under the columns. Each row will represent a patient. The 
variables will be as follows: 
A: Patient Number 
B: Date of birth of patient 
C: Date when specimen taken 











E. Antibiotic name 
F: Sensitivity 
G: Province of origin 
H: Hospital name 
I: Ward from which sample was taken 
 
The following information will be needed:  
      - A list of the positive CSF culture results.  
- The organism cultured 
- Date of birth of the patient 
- Date when CSF specimen take 
- The name of hospital ( this won't be published) 
- The ward from which the sample was taken 
- Details of all antibiotic sensitivity testing( resistance and sensitivities)  
 
The data will be obtained from the Corporate Data Warehouse (CDW). All National 




















 Descriptive analyses such as working out the frequency distribution of various 
causative organisms will be done in Excel. Statistical analyses will be performed 
using the following software: Stata and epicalc 2000.  The prevalence of causative 
organisms per year and per age group will be calculated and depicted in bar graphs 
(error bars will depict the 95% confidence interval).  Bar graphs for each year will be 
created and this will depict trends over time .The prevalence ratio will also be used to 
compare the causes of meningitis between the various age groups.  
 The relative proportions of pneumococcal meningitis prior to and after the 
introduction of the conjugate pneumococcal vaccine will be calculated and depicted 
on a bar graph. (The pneumovac vaccine was included in the South African vaccine 
schedule on 1 April 2009. Children born after 15 February 2009 were eligible for the 
pneumovac vaccine 
xii
  .The assumption will be that patients born after 15 February 
2009 were vaccinated with the conjugate pneumococcal vaccine.) This will also show 
the change  of  prevalence of pneumococcal meningitis over time.  The antibiotic 
resistance and sensitivity patterns among the organisms causing bacterial meningitis 
in neonates and children will be calculated. Organisms will be looked at individually 
and the rate of resistance to the relevant antibiotics will be calculated. 
The chi-squared test will be used to test the hypotheses.  The level of significance will 















D Ethics and Communication: 
1. Ethics:  
The data used will be unlinked; i.e. the names of the patients will not be part of the 
data set. The data will be obtained only after receiving consent from the Corporate 
Data Warehouse. This study does implement the ethical principals of justice, 
beneficence and non – malificience. The study will benefit the paediatric population 
of South Africa because it will give health care professionals an insight into the 
causes of meningitis and will help in future treatment and preventative strategies 
(justice). The study will pose no harm to paediatric patients. (non- malificience) 
 
2. Reporting and implementation: 
The results of this study will be fed back to the school of child and adolescent health 
at UCT. The study will be written up for an MMed and will be submitted for 
publication. The feedback will serve as a platform to inform colleagues about 
meningitis among the South African paediatric population. It may also open up new 
research questions and lead to more studies. 
E. Logistics:  
This study will not require many resources. The following resources will be required:  
Access to a computer, certain software packages and access to the internet. These 
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Bacterial Meningitis in neonates and children in South Africa: a literature review 
Background: 
Acute bacterial meningitis is an important cause of morbidity and mortality in newborns and 
children.
1
 In South Africa the fatality rate among infants and children due to bacterial 
meningitis is between three to seven percent.
2
Bacterial meningitis is defined as inflammation of the meninges.
1 
A bacterial agent colonizes 
the nasopharynx and then invades the nasal mucosa. This is followed by bacteraemia and 
subsequent entry of bacteria into the cerebrospinal fluid and the meninges.
3
 Acute bacterial meningitis is caused by various bacteria and the specific aetiology is age 
dependant.
4
 The epidemiological pattern, as well as morbidity and mortality of bacterial 
meningitis is also dependant on geographical location.
1,3 
Developing countries have a higher 
mortality as well as a different epidemiological pattern as compared to developed countries.
3 
 
Review articles have documented the common causes of acute bacterial meningitis in various 
age groups. In the neonatal period the common causative organisms are: Group B 
Streptococci, Gram negative bacilli (e.g.:  E. coli, Klebsiella spp, Enterobacter spp, 
Salmonella spp) and Listeria monocytogenes.
4 ,5 
The causative organisms in the age group 1 – 
3 months are the same as the neonatal age group as well as Streptococcus pneumoniae, 
Haemophilus influenzae Type B (Hib) and Neiseria meningitidis. 
1, 4, 5 
In infants and children 
aged 3 months to 5 years the most common causative organisms are: S. pneumoniae, Hib and 
N. meningitidis.
1, 4, 5 
The two chief causes of bacterial meningitis in children older than 5 
years old are: S. pneumoniae and N. meningitidis.
1, 4,5 
 
Knowing the most common causes of bacterial meningitis in the various age groups helps 
health professionals to initiate the best possible empiric antibiotic therapy.
1,4,5  












review articles  recommended the following empirical antibiotic regimes for meningitis: age 
less than 1 month: ampicillin plus either gentamicin or cefotaxime; age 1 – 3 months: 
ampicillin plus either cefotaxime or ceftriaxone, (vancomycin can be added if pneumococcal 
meningitis is suspected); ages 3 months – 21 years: cefotaxime/ceftriaxone plus either 







 The essential drug list for South African paediatrics recommends the 
following empiric treatment regimes: neonates: ampicillin plus either cefotaxime or 
ceftriaxone; children> 60 days: cefotaxime or ceftriaxone.
7
   
With the advent of preventative strategies, especially new vaccines such as the Hib vaccine 
and the pneumococcal conjugate vaccine, one would expect a change in the incidence of 
certain causative organisms.
 1 
The Hib vaccine has caused a 99% reduction in Hib invasive 
disease in developed countries.
4 
The conjugate pneumococcal vaccine (pcv) has also been 
shown to have substantially reduced the incidence of pneumococcal meningitis in children 
younger than 5 years in many high – income countries.
 1  
It is important to note that in Africa 
the Hib and pcv have not been widely implemented.  
Recent review articles on bacterial meningitis focus more on developed countries and there is 
less information on meningitis in developing countries. In this literature review, an emphasis 
has been made on meningitis in developing countries, especially African countries. It is also 
important to note that the conjugate pneumococcal vaccine was not available in Africa.  
Objectives: 
This literature review on the aetiological agents of bacterial meningitis among neonates and 













-  identify the common causative organisms of acute bacterial meningitis in neonates 
and children in both developed and developing nations; 
-  review the impact of the Hib and pneumococcal vaccines on haemophilus and 
pneumococcus meningitis; 
-  review the antibiotic sensitivity patterns of the common causative organisms of 




The literature review search was conducted on PubMed (www.ncbi.nlm.nih.gov/pubmed) 
Two search strings were used: 1. Acute bacterial meningitis in children and newborns. 
PubMed searched using the following search strategy: “Acute AND (meningitis, bacterial) 
OR (meningitis) AND (bacterial) OR (bacterial meningitis) OR (bacterial) AND (meningitis) 
AND (infant, newborn) OR (infant) AND (newborn) OR (newborn infant) OR (newborns) 
AND (child) OR (child) OR (children) 
2. Acute bacterial meningitis in newborns and children in South Africa. 
 
The inclusion criteria were: English language articles; articles focusing on bacterial 
meningitis in newborns/ neonates and children (newborns/neonates were defined as age less 
than or equal to 28 days; children were defined as age less than 18 years). Articles that did 
not exclusively focus on meningitis and or children and newborns, but those which did 
include the above subjects were also included in this literature review.  
The main criteria for inclusion was studies looking at the various aetiological causes of acute 
bacterial meningitis among children and newborns/neonates but those articles focusing  on at 












Exclusion criteria were as follows: articles focusing solely on adults (defined as older than 18 
years old); articles focusing on only one bacteriological cause of meningitis, articles that 
reported only on diagnostic procedures or only on sequelae of meningitis, articles on 
meningitis not caused by bacteria and articles published in languages other than English. 
Abstracts derived from the above mentioned PubMed search were reviewed. Those abstracts 
that had any exclusion criteria were excluded. Those with inclusion criteria were reviewed in 
full text. Those articles reviewed in full text were further filtered. Those that met the 
inclusion criteria stated above but did not separate out the meningitis data or where the 
meningitis data represented a very small number of the total number of subjects studied were 
also excluded. Those studies which had patient cohorts already included in other more 
comprehensive studies were excluded.   
Reference lists of fully reviewed articles were also screened for other articles to include in 
this literature review. Articles obtained from colleagues (i.e. project supervisor and scientific 
review panel) were also reviewed and if they met the inclusion criteria they were included in 
the literature review.   
Results: 
The PubMed search was first conducted on 5 January 2011. (The same search was repeated 
on 20 June 2011 at the time of writing the literature review so as to ensure that the literature 
review was as current as possible. This was again repeated on 17 January 2013 just prior to 
submission.) The two search strings yielded 257 articles. Those abstracts as well as those 
obtained from colleagues were reviewed. The inclusion and exclusion criteria as defined in 
the above ‘Search Strategy’ section were applied and 33 articles were reviewed in full text.  
Twenty articles were included in this literature review. Twelve studies were from developing 












Africa). Seven studies were from developed nations (1 from Asia, 3 from Europe and 3 from 
the United States of America).   
The data was collected from 1974 – 2009.  One study included children and adults as the 
subjects, 2 studies focused only on neonates, 5 studies looked at children only, 9 studies 
focused on neonates and children while 3 studies looked at bacterial meningitis in neonates, 
children and adults. Seventeen articles looked at all the aetiological agents responsible for 
bacterial meningitis in their study populations. The three studies conducted in the United 
States of America (USA) only looked at three (S. pneumoniae, H. influenzae and N. 
meningitidis)
8
 or five aetiological agents (H. influenzae, S. pneumoniae, N. meningitidis, L. 




Nineteen studies’ main objective was to look 
at the causative organisms of meningitis. Of these studies only two looked at bacterial as well 
as viral aetiologies.
11,12 
 One study mainly looked at how to diagnose bacterial meningitis but 




As stated before there were six articles from South Africa. One article only looked at 
meningitis exclusively in neonates
14
. Not one of the South African articles looked at subjects 
from more than one South African province. Five studies
11,12,14 15, 16
 were conducted in the 
Western Cape and one study was conducted in Gauteng
17
. The study exclusively looking at 
neonatal meningitis was conducted at a tertiary care hospital in the Western Cape.
14 
It was a 
retrospective study and the data derived was from an 11 year period. The most common 
causative organism identified was group B streptococci. This was followed by E. coli and K. 
pneumoniae. If one looked at the gram negative bacilli as a whole group, then this group was 
responsible for the most cases of neonatal meningitis. The incidence of neonatal meningitis 













N. meningitidis was the most common cause of bacterial meningitis four of  the South
African studies looking at bacterial meningitis in children.
 11,12,15,17
  The most recent study
found that the commonest non mycobacterium cause of  childhood bacterial meningitis was 
S. pneumoniae.
16 
In the Johannesburg study, almost all of the H. influenzae cases occurred in
children 1 month – 3 years old.
17
Two of these studies reported on neonatal meningitis 
separately
12,17
Gram negative bacilli and group B streptococci were the predominant 
organisms in neonatal meningitis.
12,17
Three studies reported on antibiotic sensitivity patterns.  H. Influenzae was found to be 
resistant to ampicillin in 2/34 (6%) of cases in one study
12
while none of the H. influenzae
isolates were resistant to chloramphenicol in another study.
17
Of the N. meningitidis isolates 
24/ 114 (21%) were resistant to sulphonamides in one study
12
while 6/18 (33%) were
resistant in another.
11
8/17( 47%) of S. pnuemoniae isolates were resistant to penicillin in the 
Johannesburg study
17
, while none of the  28 S. pnuemoniae isolates in a Western Cape study
were resistant to penicillin .
12
Only one of these studies was conducted in the era of the Hib vaccine
16
and none were
conducted in the era of the pneumococcal conjugate vaccine.
Other developing countries
Six African studies were included in this literature review. Three studies were conducted in 
rural areas
18 ,19, 20
while three studies were based in urban centres.
21 , 22, 23
In the neonates the 
most common causative organisms were Group B Streptococci and gram negative bacilli in 
two studies
18,23
, while one study found that S.pneumoniae was the commonest causative
organism of neonatal meningitis followed by E. Coli ( gram negative bacilli).
21
S. 
pneumoniae and H.influenzae were the main causative organisms in infants and children in all 
the African studies looked at in this literature review
. 18-23
Four of the studies found that the














S.pneumoniae isolates tested in a Kenyan study 26% were resistant to penicillin
18.
 Three 
studies found relatively high resistance to ampicillin and chloramphenicol among H. 
influenzae isolates (> 20%).  
18,22,23
 The two studies which reported on N. meningitidis 
sensitivity stated that all isolates were sensitive to penicillin and chloramphenicol.
20,22 
None 





The only other study from a developing nation included in this literature review was from 
India.
24
 This was a retrospective study which looked at bacterial meningitis in neonates, 
children and adults. The total number of children from 0 – 12 years was 41. The most 
common organism isolated among this age group was S. pnuemoniae.
24 
Significantly there 




The most common causative organism of neonatal meningitis in the United States of 
America, as documented by two studies was group B streptococci.
 9,10
 This too was the case 




The three studies from the USA, included in this literature review also looked at the impact of 
preventative strategies, most notably the introduction of the Hib vaccine and the 
pneumococcal conjugate 7 – serotype vaccine (PCV7). The median age of meningitis was 
found to have shifted from 15 months to 25 years old after the introduction of the Hib 
vaccine.
9 
The proportion of cases due to H. Influenzae decreased from 58% to 15% after the 
introduction of the Hib vaccine
8 
S Pneumoniae was the predominant organism in infants and 











meningitis in older children.
9,10
Antibiotic sensitivity patterns were reported on in one 
American study.
9
9/12 (75%) of H.influenzae isolates tested were sensitive to ampicillin. Of
the S. pneumoniae isolates tested, 54/84 (12 %) were resistant to penicillin.
9
The rates of 
bacterial meningitis were found to have decreased sharply among children after the
introduction of PCV 7.
10
Three studies from Europe were included in this literature review. One study exclusively
dealt with neonates and its findings have already been reported on above. 
25
A 32 year study
conducted in Greece found that N. Meningitidis was the most common causative organism
among infants and young children (incidence rate = 8,9/ 100 000 children) followed by S.
pneumoniae (incidence rate 1,3/ 100 000 children).
26
The incidence rate of H. influenzae
declined after the introduction of the Hib vaccine.
26
This was in contrast to a study conducted 
in Lithuania where the most common causative organism was H. Influenzae.
13
The last article looked at from a developed nation was conducted in Korea. 
27
This 10 year 
retrospective study concluded that the most common causative organism among neonates was 
Group B streptococci. The two most common organisms responsible for bacterial meningitis 
in infants beyond the neonatal period and children were S. pneumoniae and H. influenzae.
27




Acute bacterial meningitis is an important cause of morbidity and mortality among newborns 
and children.
1
It is thus imperative that one understands the epidemiology of acute bacterial 
meningitis. It is also important to establish whether certain preventative measures have had 












In the neonatal period the most common causative agents are group B streptococci and the
gram negative bacilli. The only African study which deviated from this trend was the study
conducted in the Gambia where S. pnuemoniae was the most common causative organism in 
neonatal meningitis.
21
Significantly it seems that group B streptococcal infection is a disease
of the developed and developing world. The use of intra partum antibiotics in women in the
USA has not reduced the risk of late – onset (older than 7 days) group B streptococcal disease
but it has reduced the risk of early onset infection.
10
The South African study reporting on 
neonatal meningitis stated that 35% of the group B streptococcal infections occurred before
72 hours of age and that it was responsible for 48% of all cases of neonatal meningitis 
presenting within 7 days of age. It failed to state the percentage of group B streptococci 
presenting after 7 days of age.
14
One, could, however deduce that the implementation of intra
– partum antibiotics in women who screened positive for group B streptococci in South 
Africa could in the future prevent almost half of the cases of early onset neonatal meningitis.
The African studies failed to make a distinction between early and late onset group B 
streptococcal meningitis.
18,23
Causative organisms: older children 
Unlike neonatal meningitis, the causative organisms in childhood meningitis varied from 
region to region. In South Africa four studies reported that N. meningitidis was the most 
common causative organism of childhood meningitis.
11,12,15,17
 One of the Western Cape
studies
11
, however was conducted during a time when Cape Town was experiencing a
meningococcal outbreak
28
. This could explain the preponderance of meningococcal
meningitis.
 
 None of these four studies were conducted in the era of Hib and PCV7. One 











the incidence of acute bacterial meningitis and that their use be recommended.
15
The most
recent study was conducted in the era of the Hib vaccine. 
16
The incidence of H. influenzae
was only 1 %. 
16
The other African studies found a different pattern. They found that S. pnuemoniae and H. 
influenzae were the most common causative organisms in childhood meningitis.  The authors 
of the African articles made a strong case for the implementation of the Hib and 
pneumococcal conjugate vaccines.
18 - 23
A substantial amount of meningitis would have been 
prevented and the burden of disease in already stretched health care services would have been 
alleviated. 
19,23
Two articles, however, did state that in their studies the H. influenzae and 
S.pneumoniae strains were not serotyped and thus it did make it difficult to say whether or 
not the Hib and pneumococcal conjugate vaccines would have reduced meningitis caused by
these two organisms.
18,20
In the developed world countries included in this literature review, there was also a difference
in the distribution of the causative organisms of childhood meningitis. The USA articles 
found that S. pneumonia and N. meningitidis were the most common organisms. These
articles, however, only looked at a limited number of causative organisms. 
8 - 10
Europe only
contributed to 3 articles (one of which only reported on neonatal meningitis) in this literature
review so it would not be wise to generalise their findings to the whole continent. The Greek 
study, however, was a large study and it showed trends in bacterial meningitis over 32 
years.
26
N. meningitidis was the most common organism isolated. This study illustrated the
impact of the Hib vaccine with a significant reduction of H. influenzae meningitis after its 
introduction.
26
The most common causative organism in childhood meningitis in the two Asian articles was 
S. pneumoniae. 
24,27
H. influenzae was the second most common organism isolated in the












reduced the incidence of H. influenzae meningitis.
27
 This sentiment was re iterated in the 
USA studies. 
8,9
The only study which was conducted during the era of PCV7 vaccination did 
find a reduction in the rates of bacterial meningitis in children aged 1 to 23 months old.
10 
These findings show the importance of these two vaccines in reducing childhood bacterial 
meningitis.    
Antibiotic susceptibility  
As with the differences in distribution of causative organisms throughout the world, there are 
also differences in antibiotic sensitivity patterns. In South Africa there is a significant S. 
pnuemoniae resistance to penicillin in Johannesburg
17
, whereas the  Cape Town study which 
reported on S.pneumoniae sensitivity found that none of the isolates were resistant to 
penicillin
12
.The Johannesburg study was conducted over two years and looked at bacterial 
meningitis in patients (from neonates to adults) at 5 hospitals.
17 
Seventeen pneumococcal 
isolates were tested and 8/17(48%) were resistant to penicillin.
17
The Cape Town study was a 
3 year hospital based survey and it looked at meningitis only in children up to 13 years 
old.
12
In this study none of the 28 pneumococci isolated were resistant to penicillin.
12 
The 
Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS 
–SA) has published surveillance reports in the communicable diseases surveillance bulletin. 
GERMS –SA has found an increase in pneumococcal resistance to ceftriaxone and 
penicillin.
29
  It found that Gauteng had 11% resistance to penicillin, whereas the Western 
Cape had 8% resistance. GERMS –SA in fact advises that if pneumococcal meningitis is 
suspected, vancomycin be added.
29  
 In Africa H.influenzae has a high resistance against chloramphenicol.
18,22,23 
In fact the 
Kenyan authors have recommended that children at risk of H. influenzae meningitis should be 














This literature review demonstrates that there is a geographical variation in the causative 
organisms of childhood bacterial meningitis. This too, is true for the patterns of antibiotic 
sensitivities. It is, thus, important to have a good understanding of the epidemiology of acute 
bacterial meningitis in one’s own region so as to adequately treat this disease. There are 
credible preventative strategies available, most notably the Hib and pneumococcal vaccines.  
These should be widely implemented so as to reduce the burden of disease caused by acute 
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Acute bacterial meningitis is an important cause of morbidity and mortality in new-borns and 
children. Knowing the epidemiological pattern of acute bacterial meningitis in a specific area will 
help health professionals to initiate the best empiric antibiotic therapy.  
Methods: 
This was a retrospective descriptive and analytical cohort study. The subjects of this study were 
patients in the paediatric population from 0 to 12 years who had positive cerebrospinal fluid (CSF) 
cultures due to bacteria from 2005 – 2010. All provinces, whose data was captured on the Corporate 
Data Warehouse (CDW) during this time, were included. (The CDW is a public laboratory system in 
South Africa recording all culture results.)  
Results: 
 The sample size was 6030.    
In neonates the most common causative organisms were Gram negative bacilli : 32.1%; 95% CI: 
29.4% - 34.8% ( n/N = 378/1178) and Group B Streptococcus : 30.5%; 95% CI: 27.9% – 33.1%          
(n/N= 359/1178) . Listeria monocytogenes contributed 0.2%. (n/N= 2/1178)  
S. pneumoniae was the most common causative organism in children > 3 months.  
The prevalence of S. pneumoniae prior to the conjugate pneumococcal vaccine was 40.3% while after 
the introduction the prevalence was 21% . (p – Value < 0.001) 
Conclusion:  
The most common causative organisms in the neonatal period were gram negative bacilli and group B 
streptococci. S. pneumoniae was the most common causative organism of bacterial meningitis among 
South African children > 3 months. The advent of the conjugate pneumococcal vaccine has seen a 
decrease in the prevalence of S. pnemoniae. 













Bacterial meningitis is an important cause of morbidity and mortality in new-borns and 
children.
1
In South Africa the fatality rate among infants and children due to meningitis is between 3 
and 7%.
2
Developing countries have a higher mortality as well as different epidemiological 
patterns compared to developed countries.
3
Knowing the most common causes of bacterial 
meningitis in various age groups helps health professionals to initiate the best empiric
antibiotic therapy.
1,4,5
Previous studies conducted in South Africa looked at subjects from 
only one province (either the Western Cape or Gauteng). 
6,7,8,9,10 ,11
The most common cause 
of childhood bacterial meningitis reported by four of the studies  was Neiseria meningitidis
6,7,9,10
 while the organisms most commonly responsible for neonatal meningitis were Gram
negative bacilli and group B streptococci.
7,8,10
These studies also demonstrated a higher 
prevalence of Penicillin resistant Streptococcal pneumoniae isolates in Johannesburg
compared to the Western Cape.
7, 10
The most recent South African study found that the 
commonest non mycobacterium cause of bacterial meningitis was S. pneumoniae.
11
This 
study also found that antibiotic pre – treatment may have resulted in an underestimation of   
CSF culture – positive meningococcal cases. 
11
The Haemophilus B (Hib) vaccine was introduced in South Africa in 1999 while the 
pneumococcal conjugate vaccine was included in the South African vaccine schedule on 1 














 The role out of the pneumococcal vaccine was, however unequal in 
each province. 
  
The aim of this study was to investigate the aetiology of non - Tuberculosis bacterial 
meningitis in South African new-borns and children from 2005 – 2010 and to assess the 
change in prevalence of organisms prior to and after the introduction of the conjugate 
pneumococcal vaccine.  
 
Methods: 
This was a retrospective descriptive and analytical cohort study. 
Subjects 
The subjects of this study were patients in the paediatric population (0 – 12 years of age) who 
had positive cerebrospinal fluid (CSF) culture results from 2005 – 2010. All provinces, 
whose data was captured on the Corporate Data Warehouse (CDW) during this time, were 
included. (The CDW is a public laboratory system in South Africa recording all culture 
results.) 
This sample represented the paediatric population who made use of government hospital in 
South Africa.  
Data  
Data was obtained from the CDW. All provinces except for Kwazulu Natal were included. 
(Kwazulu Natal’s data was not captured on the CDW for the time period of this study). The 
following data was requested: all positive non Tuberculosis bacterial CSF culture results 
(from age 0 – 12) from 1 January 2005 to 31 December 2010,  the date of birth, the date when 
the CSF specimen was taken, the name of the hospital and ward from where the CSF sample 











or resistance to a particular antibiotic and the method of ascertaining susceptibility was not 
stated.  Even though only date of birth was requested the CDW did give the age of each 
patient. The CDW defined age in days, months and years.     
This study did not include positive blood cultures or subjects with probable meningitis but 
not proven on CSF culture.  
Inclusion criteria: 
- All positive non Tuberculosis bacterial CSF culture results (from age 0 – 12) from 1
January 2005 to 31 December 2010
Exclusion criteria: 
- Positive CSF cultures due to Mycobacterium tuberculosis and fungi were. 
- Patients who had no age documented.
- Patients older than 12 years.
Measurement
A database was created in Microsoft excel onto which variables of interest were entered:
patient number, age of patient when sample taken, date when sample taken, organism grown, 
antibiotic name, susceptibility, province of origin, hospital name, ward from which specimen 
taken. 
Analyses
Descriptive analyses were done in Excel. Statistical analyses were performed using StataIC
version 11. The proportion of causative organisms per age group was calculated for the 
overall sample. The proportion of causative organisms was then calculated for each calendar 
year. Early neonatal period was defined as age 0 – 7 days old whereas the late neonatal period 
was defined as > 7 days old. The proportions of group B streptococcus in the early vs late
neonatal period were calculated. The relative proportions of causative organisms prior to 












2005 – 2008 were defined as ‘pre vaccine’ and years 2009 – 2010 were defined as ‘post 
vaccine ’.  The chi-squared test was used to assess difference in prevalence and proportions 
before and after the introduction of the conjugate pneumococcal vaccine. Antibiotic 
resistance and susceptibility patterns were described. The level of significance for all 
analyses was p <= 0.05.
Results: 
Sample 
Seven thousand eight hundred and eighteen samples were obtained from the CDW.  
Unfortunately 1504 had no date of births and were defined as 0 days, 0 months and 0 years, 
57 were over 12 years of age, 11 were due to Candida, 5 were due to Cryptococcus and 211 
were due to M. tuberculosis. These were excluded and this left a total sample size of 6030.     
(Figure 1)  The distribution among the years was as follows: 2005:411; 2006:1186; 
2007:1140; 2008: 1135; 2009:1090; 2010: 1068.  
The break down per age group was: 
1. 0 – 28 days: 1178 
2. 1 – 3 months: 711 
3. > 3 months to 5 years: 3166 
4. > 5 years – 12 years:975  
Organisms by age group from 2005 - 2010 
Neonatal period (0 – 28 days) 
In the neonatal group the most common causative organisms were Gram negative bacilli: 
32.1%; 95% CI: 29.4% - 34.8% (n/N= 378/1178) and group B streptococcus 30.5%; 95% CI: 
27.9% – 33.1% (n/N= 359/1178). The majority (73.5%) of group B streptococcus occurred 
after 7 days whereas 26.5% occurred in the early neonatal period.   Coagulase negative 











95% CI: 10.7% - 14.5% (n/N= 148/1178). Listeria monocytogenes only contributed 0.2%      
(n/N=2/1178). (See figure 2) 
1-3 months:
The 1 – 3 month group had a different distribution of organisms with Gram negative bacilli 
contributing 31.1%; 95% CI: 27.7% - 34.5% (n/N= 221/711)  and S.pneumoniae 23.4%; 
95%: CI 20.2% - 26.5%( n/N= 166/711). (See figure 3) 
>3 months – 5 years:
S. pneumoniae: 44.6%; 95% CI: 42.9% – 46.4%( n/N= 1413/3166) was the most common
organism in the 3 month – 5 year age group. Gram negative bacilli accounted for 17.6 %;
95% CI: 16.3% - 18.9% ( n/N= 557/3166) while CONS comprised 10.9% ; 95% CI: 9.8% -
12% ( n/N = 344/3166). Neisseria meningitidis and Haemophilus influenzae contributed 
8.1% ; 95% CI: 7.1% – 9% ( n/N= 255/3166) and 4.5% ;95% CI: 3.7% -5.2% (n/N=
141/3166) respectively. (See figure 4)
> 5 years – 12 years:
S. pneumoniae :55.5%; 95% CI: 52.4% – 58.6% (n/N= 541/975) emerged as the most
common organism in the >5 – 12 year age group. Gram negative bacilli contributed 10.1%; 
95% CI: 8.2% - 11.9% ( n/N= 98/975) while N. meningitidis and H.influenzae accounted for
7.90% ;95% CI 6.2% – 9.6% ( n/N = 77/975) and 2.7% ;95% CI: 1.7% – 3.7% (n/N= 26/975)
respectively. Coagulase negative staphylococci also featured with a prevalence of 10.9% ; 
95% CI: 9.8% - 12%( n/N= 106/975). (See figure 5).
A chi square test showed that the difference in distribution of organisms per age group and 
per year was statistically significant (p –value < 0.001). 
The following graphs show the change of prevalence of each organism per year and per age












Proportion of causative organisms pre- and post the conjugate pneumococcal vaccine: 
Of the 6030 samples, 1102 were eligible for the vaccine. Table 1 depicts the prevalence of 
causative organism pre – and post the conjugate vaccine era, as percentages of total cases of 
meningitis. (See Table 1). 
Table 2 depicts the difference between the absolute yearly number of organisms from 2006 – 
2008 compared to 2009 – 2010 (the vaccine era). The year 2005 was excluded due to the 
limited amount of CSF samples from that year. (See Table 2). 
Antibiotic susceptibilities: 




There is a difference in distribution of common causative organisms according to age. 
Neonates (0 – 28 days) 
The chief causes of acute bacterial meningitis in this age group were gram negative bacilli 
and group B streptococci.  This is in keeping with international
4, 5
 and national literature.
8
The 
prevalence of the gram negative bacilli decreased in 2009 and 2010 whereas the prevalence 
of group B streptococci remained steady over the 5 years.  The significant contribution of the 
group B streptococci raises the possibility that the implementation of intrapartum antibiotic 
therapy in women who are positive for group B streptococci might have decreased the 
prevalence of neonatal meningitis. In the United States of America (USA) the use of 
intrapartum antibiotics reduced the risk of early but not late onset infection.
13 , 5
 Unfortunately 
the bulk of group B streptococcal meningitis occurred in the late
 
neonatal period  and thus the 
use of intrapartum antibiotics might not have had a marked effect. Other preventative 











is a strategy that is being considered in other settings. 
5
L. monocytogenes is a very rare cause 
of meningitis in our setting, accounting for 0.17%. This is in keeping with a previous South 
African study on neonatal meningitis which found only one L. monocytogenes isolate.
8
The
third most common causative organism in this age group is the coagulase negative
staphylococci (CONS). Although CONS are usually regarded as contaminants, in sick 
neonates they should be considered as pathogens.
14
One can only assume that the neonates 
included in this study were ill enough to warrant a lumber puncture and that the CONS
isolated were in fact, significant. 
1 – 3 months:
This age group represents an interim period between the neonatal period and early childhood. 
The most common causative organisms were the gram negative bacilli and S. pneumoniae. 
International guidelines state that empiric antibiotic therapy in this age group should include
ampicillin to cover for L. monocytogenes.
1
Interestingly, of the six L. monocytogenes 
isolated, none of them were cultured in this age group.
>3 months – 5 years:
The most common causative organism in this age group was S. pneumoniae. This is in 
keeping with studies conducted in the USA as well as a recent South African study
1113 , 15
This is, however, in contrast to older South African studies which revealed that N. 
meningitidis was the most common causative organism among children. 
6, 7, 9, 10
Antibiotic pre
– treatment may have resulted in an underestimation of   CSF culture – positive
meningococcal cases. This was seen in a recent South African study.
11
The prevalence of S. pneumoniae remained above 40% from 2005 to 2009 with a reduction to 
34. 62% in 2010. (p = <0.001) This could be explained by the introduction of the conjugate
pneumococcal vaccine in 2009 as well as the effect of anti- retroviral therapy. An 
antiretroviral program was initiated in South Africa in 2004. 
16












the antiretroviral program was associated with a significant decline in the burden of invasive 




H. influenzae  B (Hib)only accounted for 4.45%. This is most likely due to the immunization 
of infants with the Hib vaccine which was implemented in 1998. Surveillance for invasive 
Hib disease in South Africa has shown a significant decrease since the introduction of the Hib 
vaccine.
12 
Coagulase negative staphylococci accounted for 10.87%. Unfortunately, the 
technique and circumstances  in which the CSF samples were collected was not documented 
in this study. The presence of coagulase negative staphylococci could indicate poor sterile 
technique, specimen collection to culture delay, errors with laboratory sequencing or a 
nosocomial infection. There was insufficient data to exclude nosocomial meningitis.  The 
prevalence of HIV in South Africa among children aged 2 – 14 in 2008 was 2.5%
17
 This 
could account for the marked presence of the gram negative bacilli and coagulase negative 
staphylococci in this age group.
>5 years to 12 years: 
S. pneumoniae is the commonest organism isolated. This is again, in contrast to previous 
South African studies which found that N. meningitidis was the commonest cause of acute 
bacterial meningitis among chil0dren.
 6,7,9,10
 The prevalence of this organism remained steady 
at >50% over the five years. Patients in this age group were not eligible for the conjugate 
pneumococcal vaccine and thus its impact was not seen in this age group. N. meningitidis 
was the fourth most common causative organism after S. pneumoniae, coagulase negative 
staphylococci and the gram negative bacilli. H. influenzae was not very prevalent in this 
group. Its prevalence was half than its presence in the 3 month to 5 year age group. An 
unexpected finding is the significant presence of gram negative bacilli and coagulase negative 











laboratory practices. The underlying health of the patients was also not known. It would be
interesting to see what the immune status of these patients was and if these two organism
groups occurred mainly in immunosuppressed individuals.   
Antibiotic susceptibility:
It must be emphasized that not all isolates were tested for antibiotic susceptibility. Each 
specific isolate per organism group was also not necessarily tested for susceptibility against
the same antibiotics. The data obtained stated sensitivity or resistance to a particular 
antibiotic and the method of ascertaining susceptibility was not stated. Unfortunately the
CDW does not reflect centralised testing but rather testing as done by all the regional national 
health laboratory services (NHLS) laboratories . 
The following empiric treatment regimes for bacterial meningitis are recommended: < 1 
month: ampicillin plus either gentamicin or cefotaxime; 1 – 3 months: ampicillin plus either 
cefotaxime or ceftriaxone (add vancomycin if pneumococcal meningitis is suspected) ; 
3months – 21 years: Either cefotaxime or ceftriaxone plus either vancomycin or rifampicin 
( in areas with a high incidence of resistant S. pneumoniae)
1
 The most common causative organisms in the neonatal age group were gram negative bacilli 
and group B streptococci. Of the group B streptococci that were tested, 98.88% were 
susceptible to penicillin/amoxicillin/ampicillin. The gram negative bacilli had only 56.4% 
susceptibility against gentamicin. This group had higher susceptibility (> 80%) against 
amikacin and meropenem.  A proportion of isolates may not be covered with first line 
antibiotics. It may be prudent when dealing with gram negative bacilli to consider changing 
antibiotics. The gram negative bacilli had a high resistance against third generation 
cephalosporins. This may indicate nosocomial gram negative infection. 
Current recommendations are for Ampicillin to be added in meningitis treatment regimens to 











amoxicillin. This rare cause of meningitis in South Africa will therefore be covered by 
current antibiotic regimes.  
Numerous S. pneumoniae isolates (1104) were tested for susceptibility against the third 
generation cephalosporins with a 98.46% sensitivity and 1789 isolates were tested for
susceptibility against Penicillin/Ampicillin/Amoxicillin with a 70.88% susceptibility. This 
data therefore supports the use of empiric third generation cephalosporin for treatment of 
childhood meningitis. The Group for Enteric, Respiratory and Meningeal disease
Surveillance in South Africa (GERMS – SA), however still recommends that Vancomycin be
added if pneumococcal meningitis is suspected.
18
Apart from outliers in 2005 N. meningitidis 
and H. influenzae both had high rates of susceptibility to third generation cephalosporins.
The impact of the conjugate pneumococcal vaccine:
The 7 – valent conjugate pneumococcal vaccine was introduced into the South African 
vaccination schedule in 2009.
12
Children born after 15 February 2009 were eligible for the
vaccine and no catch up immunisation was planned.
12
Unfortunately this study looked at data
from 2005 – 2010 and thus there were fewer samples collected in the post vaccine era. 
Nonetheless, the data revealed that there was a statistically significant reduction in the
prevalence of S. pneumoniae meningitis from 40.29% in the pre vaccine era to 20.96% in the
post vaccine era (p – value < 0.001). A similar finding was reported by GERMS – SA which 
found that there was a decrease in invasive pneumococcal disease in infants less than 1 year 
in 2009.
18
This was attributed to the introduction of the conjugate pneumococcal vaccine that 
same year.
18
It would be interesting to look at more extensive data dating from the point of
the conjugate vaccine introduction to present day. One would hope that the early trend of 











the 7 – valent vaccine may lead to a shift in prevalent pneumococcal serotypes and this may 
be a threat to vaccine success. With this in mind the 13 – valent conjugate pneumococcal 
vaccine was introduced into the South African vaccination schedule in 2012. Further research 
may reveal whether this vaccine will have additional impact. 
With the decline in S. pneumoniae meningitis there was an increase in some of the other 
organisms. Those that significantly increased were: coagulase negative staphylococci, 
enterococci, Methicillin resistant S. aureus, group B streptococcus and the gram negative 
bacilli. This however, may be an artefact due to the declining number of S. pneumoniae 
isolates causing a lower denominator.  
Limitations:
This data was obtained from a data warehouse. There is no information on how the specimens 
were collected. Not all organisms isolated were tested for antibiotic sensitivities. The data 
obtained stated sensitivity or resistance to a particular antibiotic and the method of 
ascertaining sensitivity was not stated. Although the number of specimens collected were
fairly similar from 2006 – 2010, there were far fewer samples collected in 2005, when the 
progress was just beginning. There was insufficient data to determine the prevalence of 
nosocomial infections and the amount of positive CSF cultures from neurosurgical wards.














The most common causative organisms in the neonatal period are gram negative bacilli and 
group B streptococci.  L. monocytogenes is a rare cause of acute bacterial meningitis among 
South African newborns and children. S. pneumoniae is the most common causative 
organism of bacterial meningitis among South African children > 3months. The conjugate 
pneumococcal vaccine has significantly decreased the absolute prevalence and the relative 
proportion of S. pnemoniae meningitis.  
Funding: No funding was required. 






























 Figure 1: Logarithm of CSF disposition 
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Prevalence of causative organisms in the neonatal period from 2005 to 2010 (error bars depict the 95% 
confidence interval) 






























       
 Figure 4: Prevalence of causative organisms among infants and children aged >3 months to 
five years from 2005 to 2010 
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Figure 6: Distribution of the coagulase negative Staphylococci per age group and per year 
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Figure 8: The distribution of the Gram negative bacilli per age group and per year 
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Figure 10: The distribution of H. influenzae per age group and per year: 
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Figure 12: The distribution of Methicillin resistant S. aureus ( MRSA) per year and per age 
group 
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Figure 15: The distribution of S. pneumoniae per age group and per year 
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Figure 17: The distribution of other streptococci per age group and per year 
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 Table 1: The effect of the conjugate pneumococcal vaccine: 
Organism Pre 
vaccine %      
(n/N) 
95% CI Post 
vaccine% 
(n/N) 








13.3%   
(147/1102) 









3% - 5.3% 0.003 






















2% - 4% 0.693 





Methicillin Resistant S. 







1.8% - 3.7% <0.001 













3.2% - 5.6% 0.5 















0.4% - 1.5% 0.385 
























Table 2: The effect of the conjugate pneumococcal vaccine from years 2006 - 2010 
Organism Pre 



















11.4% 128 10.5%- 
12.3% 
13.3% 139 11.3%- 
15.4% 
0.073 
Enterococci 2.5% 29 2.1% - 
3.1% 
4.2% 38 3%-5.4% 0.005 
Gram negative 
bacilli 
19.3% 230.7 18.1% - 
20.4% 





5.6% 82.3 5% - 
6.3% 
15.1% 87 13% - 
17.2% 
<0.001 
H. influenzae 3.4% 37 2.8% - 
3.9% 
3% 37 2% - 4% <0.001 
L. 
monocytogenes 
0.1 2 0.03% - 
0.2% 
0% 0 N/A 0.226 
MRSA 1.2% 13.3 0.8% - 
1.5% 
2.7% 21 1.8% - 
3.7% 
<0.001 
N. meningitidis 6.4% 70.7 5.7% - 
7.2% 
3.3% 57.5 2.2% - 
4.3% 
<0.001 
S. aureus 3.9% 41.3 3.3% - 
4.5% 
4.4% 50 3.2%- 
5.6% 
0.484 
S. pneumoniae 40.1% 451 38.7% -
41.6%





1.2% 10.4 0.8% - 
1.5%





3.1% 35 2.6%- 
3.6% 
3.7% 37.5 2.6% - 
4.8% 
0.276 
Other 1.8% 22.3 1.4% - 
2.2% 















Table 3: Antibiotic susceptibilities: 



















Amikacin 679 87.1% 83.8% 76.3% 85.6% 84.1% 85.8% 83.5% 
Gentamicin 883 64.5% 58.6% 54.7% 56.7% 53.6% 54.1% 56.4% 
Meropenem 604 92.9% 93.8% 82.4% 84.1% 88.4% 88.5% 87.9% 
Third generation 
cephalosporins 






447 100% 95.5% 100% 98.7% 100% 100% 98.9% 
H.influenzae Third generation 
cephalosporins 













N.meningitidis Third generation 
cephalosporins 




328 96.6% 97.8% 98.2% 98% 90.2% 100% 97% 
S.pneumoniae Penicillin / 
Amoxycillin/ 
Ampicillin 
1789 76.3% 72.7% 66.3% 72.7% 71.2% 67.6% 70.9% 
Third generation 
cephalosporins 
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Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
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1.1 Does this protocol receive US Federal funding? 10 Yes l IB'" No 
2. Protocol status (tick ,() 
0 Research-related activities are ongoing 
rzt' Data collection is complete. data analysis only .--
0 All research-related activities are complete (Le. final report) 
3. Protocol summary 
Total number of records or specimens collected, reviewed or stored since the original 
approval Go'S I 
Total number of records or specimens collected, reviewed or stored since last progress / 
Have any research-related outputs (e.g. publications, abstracts. conference DYes lifNo 
presentations) resulted from this research? 
If yes, please list and attach with this report. 
My signature certifies that I will maintain the anonymity and/ or confidentiality of infonmation collected in this 
research. If at any time I want to share or re-use the information for purposes other than those disclosed in 
the original approval, I will seek further approval from the HREC. 
Signature of PI 
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To:  Alex Jennings, 
Re: Permission to obtain data from the CDW 
 
I am a paediatric registrar at UCT and would like to request data from the CDW from 
the year 2005 - 2010. I would like to use this data for a MMed study.   
I will not require the names of the patients and thus the data will be anonymous.  I 
would, ideally, like to look at data from all provinces whose data is captured on the 
CDW.   
 
The intent is to examine bacterial meningitis with the following objectives in mind: 
- To determine the prevalence  (and 95 % confidence interval) of causative                          
organisms of acute bacterial meningitis among culture positive cerebral spinal 
fluid (CSF) in four paediatric periods namely: 1. The neonatal period (day 0 – 28 
days of life); 2. 1 – 3 months; 3.  3 months to 5 years) and 4. Children older than 5 
years of age up till 12 years.  If, for, example we find that Listeria is a relatively 
rare cause of neonatal meningitis, there is no intent to make any recommendations 
to change current antibiotic regimes.    
- To compare the prevalence of the causative organisms among culture positive 
CSF and the 95% confidence interval between the various age groups.  
- To determine the relative proportions of pneumococcal meningitis prior to and 
after the introduction of the conjugate pneumococcal vaccine.  
- To determine anti biotic resistance and sensitivity patterns among the 
organisms causing bacterial meningitis in neonates and children. 
The data which will be needed: 
 
1.  Positive CSF culture results of all children (in the provinces whose data is captured 
on the CDW) from birth to 12 years for the year 2005- 2010.  It would be 
advantageous if one could look at data from the whole of South Africa, but it is 
understandable if this is logistically not possible. (If this is the case, then I would just 
like to look at the data from the Western Cape) 
2. Date of birth of each patient 
3. The name of the organism grown 
4. Date of positive CSF culture 
5. Date when CSF specimen was taken  
6.The name of hospital ( this won't be published but the level of the hospital: ie: 
disrtict, regional or tertiary might be used) 
7. The ward from which the sample was taken 
8. Details of all antibiotic sensitivity testing( resistance and sensitivities)   
 
 













Corporate Data Warehouse Data Request Form No.: CDW01 
Page 1 of 3 
CORPORATE DATA WAREHOUSE 
DATA REQUEST FORM  
HELPDESK USE ONLY WORK ORDER NO. 
To have this request processed, please log a service request to Helpdesk via email or fax, together with a completed form 
(email: helpdesk1@nhls.ac.za, FAX: (011)386-6308) 
 Each application will be approved or rejected subject to the ability to extract this data and the availability of the data, and 





Tel No (083)2458308 Email karlamthomas@yahoo.com 
Supervisor name Dr J A Simpson Tel No ( ) Email john.simpson@nhls.ac.za 
Laboratory/Department (Internal) NHLS, Greenpoint 
Organisation (external) National Dept of Health /University of Cape Town 
CONDITIONS 
 Data/Information is not to be used in contravention of Sections 14, 15, 16 and 17 of the National Health Act
61 of 2004 and the Promotions of Access to information Act 2 of 2000.
 The Applicant acknowledges that this application is governed by the Data Use Agreement made between
the relevant Provincial Department of Health and the NHLS.
 The applicant undertakes to ensure that the data supplied to it by the NHLS is used ethically and solely for
the purposes for which was provided as detailed in the application, and further acknowledges that it shall
remain liable for any breaches of this clause by the end user.
 If the purpose for the data requested in this application is research, the institute’s ethics approval shall be 
attached to the application form.
 The applicant shall be entitled to include any data and /or information generated in terms of this
application, in publications and other presentations only with prior approval by the NHLS.
 The applicant shall give due credit, including affiliation, of the participation of the NHLS in any such
publications or presentations.
 The applicant and authorizing authority will be directly liable for any breach of contract.
ACCEPTANCE    *This must be completed for TB, ARV & Cervical screening data programmes
By signing this document we accept the conditions stated on page 1 
Applicant 
Dr JA Simpson 
Signature Date / /20 
Supervisor 
Dr JA Simpson 
Signature Date / /20 
APPROVAL BY BUSINESS 
Business Manager 
Mr Lunga Makamba 
Signature Date / /20 
*Programme head
N/A 
Signature Date / /20 
. 
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CORPORATE DATA WAREHOUSE  
DATA REQUEST FORM 
 
 
FIELD OF DATA 
Haematology 





Other (provide details):      
DESCRIPTION OF REQUIRED DATA 
I would like all positive CSF culture results from children aged 0 - 12 years, the name of the organism grown, the 
date which the specimen was taken, dob of each patient, the name of hospital ( this won't be published ), the 
name of the ward where the specimen was taken, , details of all antibiotic sensitivity testing( resistance and 





DESCRIPTION OF INTENDED USE OF DATA  
(e.g research, epidemiology,study, cost analysis of service, drug efficacy, disease surveillance) 




LIST WHO WILL HAVE ACCESS TO THIS DATA 
Dr Mike Levin ( Department of Paediatrics, Somerset Hospital) 
Dr JA Simpson ( NHLS, Greenpoint) 
Dr Andrew Whitelaw ( Microbiology, GSH) 
Dr Kim Bonorchis ( NHLS, Greenpoint) 
Dr Susan Meiring ( Germs SA) 
Dr Karla Thomas ( Paediatrics registrar, Somerset hospital) 





Region (for data extract e.g 
Province or Lab prefix) 
Western Cape, Eastern Cape, Free state, Guateng, Mpumulanga, Northern 
Cape, Limpopo, North West Province  
Data range of extract 2005 -2010 
Fields required e.g patient name, 
DOB, etc. 
All positive CSF culture results from ages 0 - 12 years, DOB , hospital and 
ward where specimen taken,The level of the hospital ( ie, district, regional, 
tertiary), date csf taken, name of organism grown, details of all antibiotic 
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Request Type New   Modify  Data format Excel CSV    
Frequency of 


















INSTRUCTIONS TO AUTHORS 
Please note that the journal now encourages authors to complete their copyright licence to 
publish form online 
All manuscripts must be submitted online. Once you have prepared your manuscript according to the 
instructions below please visit the online submission web site. Instructions on submitting your 
manuscript online can be viewed here. 
The International Journal of Epidemiology is produced six times a year and publishes original work, 
reviews, articles of interest and letters in the fields of research and teaching epidemiology. 
All submissions must be in the English language. 
It is a condition of publication in the Journal that authors grant an exclusive licence to the International 
Epidemiological Association. This ensures that requests from third parties to reproduce articles are 
handled efficiently and consistently and will also allow the article to be as widely disseminated as 
possible. As part of the licence agreement, authors may use their own material in other publications 
provided that the Journal is acknowledged as the original place of publication and Oxford University 
Press as the Publisher. 
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online
copyright licence to publish form. 
Please note that by submitting an article for publication you confirm that you are the 
corresponding/submitting author and that Oxford University Press ("OUP") may retain your email 
address for the purpose of communicating with you about the article. You agree to notify OUP
immediately if your details change. If your article is accepted for publication OUP will contact you using 
the email address you have used in the registration process. Please note that OUP does not retain copies 
of rejected articles 
Articles are accepted for publication on condition that they are contributed solely to theInternational
Journal of Epidemiology. The editors cannot enter into correspondence about papers considered 
unsuitable for publication and their decision is final. Neither the editors nor the publishers accept 
responsibility for the views and statements of authors expressed in their contributions.
Manuscripts should be prepared in the Vancouver Style (see e.g. Br Med J 1979; 1: 532-35) 
and submitted online here. They should not normally exceed 3000 words but review articles may be 
twice this length. Letters intended for publication should be marked 'For Publication'. Books and 
monographs for review should also be sent to the Editor.
Manuscripts should be double spaced with margins of 2.5cm. All pages should be numbered. Italics 
should be indicated by single underlining. Numbers followed by a unit should be written as figures as 
should all numbers above nine. Figures should not be used to start a sentence and those between 999 
and 9999 should not be separated by spaces or commas while those over 10 000 should have a space
after the thousand. Per cent should be written as % throughout. Full points should not be used after
initials or contractions: J Jones, FRCS, 17 g, dl, Dr, etc. All measures should be reported in SI units 
followed, in the text, by traditional units in parentheses. For general guidance on the International
System of Units and some useful conversion factors, see 'The SI for the Health Professions' (WHO, 
1977). There are two exceptions: blood pressure should be expressed in mm Hg and haemoglobin as 
g/dl. 
If the data are appropriate, age grouping should be mid-decade to mid-decade or in five-year age 
groups (e.g. 35-44 or 35-39, 40-44, etc, but not 20-29, 30-39 or other groupings). 
TITLES 
Titles should be short and specific. Subtitles may be used to amplify the main title. 
AFFILIATIONS 
The affiliations of each author must be given. If an author's present affiliation is different from that 
under which the work was done, both should be given. 
SUMMARY 
The summary should be no more than 250 words and consist of four sections labelled Background, 










study, how the study was performed, the salient results and what conclusions can be made from the 
results. Three to ten keywords should be added to the end of the Summary. 
FUNDING 
The following rules should be followed: 
The sentence should begin: ‘This work was supported by …’ 
The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National 
Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 subinstitutions) or 
'NCI at NIH’ - see the full RIN-approved list of UK funding agencies for details 
Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number 
ABX CDXXXXXX]’ 
Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, 
EFX GHXXXXXX]’ 
Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency) 
Where individuals need to be specified for certain sources of funding the following text should be added 
after the relevant agency or grant number 'to [author initials]'. 
An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 
and CA118790 to R.B.S.R.] 
and the Alcohol & Education Research Council [HFY GR667789].  
Oxford Journals will deposit all NIH-funded articles in PubMed Central. See Depositing articles in 
repositories – information for authors for details. Authors must ensure that manuscripts are clearly 
indicated as NIH-funded using the guidelines above. 
REFERENCES 
Authors are responsible for the accuracy and completeness of refer nce lists. References in Vancouver
Style should be in the order they appear in the text and numbered accordingly. These numbers should 
be inserted above the line whenever a reference is cited (...confirmed by other studies 23). Numbered 
references should appear at the end of the article and should consist of the surnames and initials of all
authors when six or less, when seven or more list just three and add et al., title of article, name of 
journal abbreviated according to Index Medicus style, year, volume, first and last page numbers,
e.g. Bull Q, Doe J. Epidemiology and public health. Int J Epidemiol 1970; 5: 702-10.
Titles of books should be followed by the place of publication, the publisher, and the year. 'Unpublished
Observations', 'Personal Communications' and submitted manuscripts may not be used as reference but 
should appear in the text. Manuscripts in press may be cited in the references and details added on 
proof if possible. 
ABBREVIATIONS 
Words to be abbreviated should be spelt out in full the first time they appear in the text with the 
abbreviations in brackets. Thereafter the abbreviation should be used. 
TABLES 
Tables should be numbered consecutively in arabic numerals and should be kept separate from the text. 
Particular care should be taken to make tables self-explanatory with adequate headings and footnotes. 
The position of each table in the text should be indicated (Table 1 here). 
FIGURES 
Illustrations should be numbered, given suitable legends. They should be kept separate from the text. 
Colour illustrations can be reproduced if there is sufficient scientific merit in doing so. Authors will be 
expected to pay for the cost of colour origination in the print version of the Journal (£350/figure). 
Alternatively, black and white figures can appear in the printed version of an article with colour versions 
appearing online (for which there is no charge). Please state your preferred option (i.e. agreement to 
pay £350/figure for print and online colour or preference for online-only colour with no charge) upon 
submission via the online submission system. 
Please ensure that the prepared electronic image files print at a legible size and are of a high quality for 
publication. For useful information on preparing your figures for publication, go 











As a general rule, material of this nature should be incorporated in the text but separate sections can be 
published after the main text. 
SPECIAL NOTES FOR STATISTICAL PAPERS 
The correct preparation of statistical manuscripts is particularly important and the precise nature and 
position of each symbol must be clear. Complex formulae should be drawn out on a separate sheet and 
attached to the text at the appropriate place.In general, distinction should be made between: 
a. capitals and small letters;
b. ordinary and bold-faced letters;
c. certain greek letters and similar roman letters;
d. subscripts, superscripts and 'ordinary' symbols.
Bold-faced symbols should be underlined with a wiggly line in pencil. Statistical symbols are 
automatically set in italics and need not be underlined except to prevent ambiguity, e.g. when an 
isolated letter, such as a, occurs in the text. Symbols should not be used to start a sentence. 
COHORT PROFILES 
Purpose: The ultimate aim of the IJE’s cohort profile series is to provide up-to-date details of cohort 
studies across the world. Each profile should include key information about a particular cohort used in 
epidemiological studies. Cohort profiles should provide IJE readers with sufficient detail to enable them 
to; form collaborations, learn from each other and maximise use of existing resources.
Word count: Around 2500-3000 (should be succinct and indicative rather than exhaustive)
Eligibility: To be eligible for publication a cohort profile MUST:
1. Have collected and completed some analyses on at least one, baseline, round of data, so that some
results in addition to baseline descriptive statistics can be presented in the profile.
2. Describe a study that has either completed prospective follow-up of participants or has funding and
clear plans to do so.
In addition to these requirements, the IJE will give preference to cohorts with over 1000 participants at 
baseline and to cohorts for which follow-up data have been collected specifically for the cohort rather
than just from routine data sources.
The IJE will accept profiles that describe cohort consortia. Such profiles should focus on the added value
of the consortium rather than piecemeal descriptions of the constituent cohorts. Updates of cohort 
profiles already published will be considered in cases where the focus of the research, or the data
collected have changed significantly. Please note that updated cohort profiles will ONLY be considered for
publication online.
From December 2012 the IJE will have a regular Data Resource Profile series. This series will cover any 
dataset of use to epidemiologists that falls outside the rubric of a cohort study. Typical examples of data 
resources include the Indian National Family Health Survey Study; UK General Practice Research 
Database (GPRD), Indonesian Family Life Survey, and Korean NHANES. However, large randomised 
controlled trials and clinical case series with long-term follow-up will also generally be considered data 
resources rather than cohorts.  
Format 
Each profile is required to follow a similar format, using the subheadings: 
Title and Author List: Your title should start with ‘Cohort Profile’ followed by the cohort name in full 
(acronyms in parenthesis). A maximum of 12 authors will be listed under the title. Additional authors 
and their affiliations should be included under the sub-heading ‘Author list continued’ at the end of the 
document. 
Summary: A short free form summary (150 – 200 words) should describe why the cohort was set up, 
cohort participants, data collection phases, main categories of data, and data access. For every cohort 
profile accepted for publication this will appear in the print version of the IJE. Please note that the 
Summary should be included in the main text document submitted to Manuscript Central. 
Key Messages A ‘Key messages’ box should be included in every cohort profile. It should not reiterate 










contributions of the cohort in terms of scientific findings. 
The Summary and Key Messages of every cohort profile accepted for publication will appear in the print 
version of the IJE. However, as the full version of some profiles will only be published online it is vital 
that the Summary and Key Messages together should provide a succinct, stand alone mini-profile of the 
study. 
Why was the cohort set up? What was the rationale for setting up the cohort including the original 
research questions it was set up to address? Where is it located and how is it funded? 
Who is in the cohort? Describe the study design; the methods used to recruit participants; numbers 
invited and numbers who entered the study (give response proportion); and differences between 
responders and non-responders at baseline (ideally as a table of socio-demographic characteristics 
comparing responders to non-responders or responders to the general population from which the 
responders came). 
How often have they been followed up? Provide details of how often questionnaires / examinations 
have been conducted. 
In addition to response at baseline, loss to follow-up over time must be described, with summary 
statistics presented in a table or figure. A description of how those lost to follow-up differ from those 
remaining in the cohort should be provided as well as the results of any work completed to describe
missing data. This section must be sufficiently detailed to provide readers with a clear picture over time 
of the population represented by the cohort. 
Please note that this section should be omitted if no follow-up data have yet been collected. 
What has been measured? 




Fasting blood samples taken, DNA extracted, fasting glucose, lipids, insulin 
assayed, serum aliquots stored at –80OC
Self-reported socio-economic position
Anthropometric measures: weight, height, waist & hip circumference
Blood pressure




Self-reported major diseases and treatment
Self-reported socio-economic position and behaviours
Ongoing All participants are flagged with routine data sources providing deaths since 
baseline and cancer registry entries since 1980 
Provide descriptions of unusual measurements (e.g. specialised scans; unique assays) and/or 
measurements that have been undertaken in sub-groups of the cohort. 
This section should describe any linkages to morbidity, mortality and other routine data sources. 
What has it found? Key findings and publications This should not be an exhaustive list, but an 
indicative summary of the most important findings generated by the cohort. If there is a web-page with 
a complete list of publications please note this and supply the web-address. The IJE strongly encourages 
authors to illustrate one or two of their main findings with a table or figure, in addition to describing the 
findings in the text. Please note it is expected that descriptions of key findings, albeit brief, will inform 
the reader what has been found rather what has been examined. 
What are the main strengths and weaknesses? Please make sure both strengths and weaknesses 
are covered. It may be useful to readers setting up new cohorts to state briefly what you would do 










anything you feel is particularly valuable but might not be possible today because of data protection or 
other difficulties. 
Can I get hold of the data? Where can I find out more? The purpose of cohort profiles is to foster 
collaboration and maximise use of existing data. If the data are open access a web address must be 
provided. If an application is required to access the data, indicate where the application form can be 
found and the process for submitting an application. If access to the data is more limited please describe 
opportunities for collaboration. In all cases the name and contact details of a researcher to whom 
enquiries and queries can be submitted must be provided. 
Please avoid using jargon and non-standard abbreviations. 
Please note that the full version of most cohort profiles submitted after the 1st October 2012 
will only be published online. Authors are reminded that both in terms of scientific merit and 
impact factor attribution, online only publication is regarded as no different from publication 
in the print version of the journal. Cohort profiles to be published in print as well as online 
will be selected by the Editors-in-chief. 
DATA RESOURCE PROFILE SERIES 
Review process: Data Resource Profiles (DRP) of potential interest to the IJE will be sent to the DRP 
handling editor. S/he will either review the submission or forward to an appropriate Editor who will seek 
external reviews, if required. Editors and external reviewers will be sent this set of instructions and 
asked to review the DRP against these. 
What are we looking for?: For this IJE section, a DRP is defined as a collection of phenotypic data 
(with or without genotypic data) relevant to human health obtained from a defined population that is 
made available to bona fide researchers for the purposes of epidemiological, demographic, social and 
other related analyses. A DRP may be globally, regionally, nationally or sub-nationally representative
and may be a single cross-sectional survey, repeated cross-sectional surveys; or large scale randomized
or quasi-randomized evaluation studies with follow up for clinical events or changes in risk factors. 
Examples of DRPs that would be considered include the Indian National Family Health Survey Study; UK 
General Practice Research Database (GPRD), Indonesian Family Life Survey, Korean NHANES.
Purpose: The ultimate aim of the IJE’s Data Resource Profile (DRP) series is to provide up-to-date
details of data resources across the world. Each profile should include key information about a particular
data resource that is currently in use or could be of use to epidemiological studies. Each profile should
provide readers with sufficient detail to enable them to understand the scope of the data resource and 
how to access and make best use of the data.
Word count: around 2500-3000 (should be succinct and indicative rather than exhaustive)
Eligibility: To be eligible for publication in the DRP profile series, a DRP must: 
• Describe a data resource to which data access is either open via a website or for which the author(s)
or their institution have the right to grant at least collaborative access via a straightforward and 
transparent application process.
• Have completed collection and have made available at least one wave of data.
Format 
Each profile is required to follow a similar format, using the subheadings: 
Title and Author List: Your title should start with ‘Data Resource Profile:’ followed by the name in full 
followed by any acronym in parenthesis. A maximum of 12 authors will be listed under the title. 
Additional authors and their affiliations should be included under the sub-heading ‘Author list continued’ 
at the end of the document. 
Summary: A short free form summary (150 – 200 words) should outline the area, units or groups 
and/or individuals covered by the data resource, data collection methods, main categories of data, and 
data access including either a web address or email address for data access enquiries or applications. 
Please note that the Summary should be included in the main text document submitted to Manuscript 
Central. 
Key Messages: A ‘Key messages’ box should be included in every DRP. In 3-4 short bullet points it 
should summarise the unique features of the data resource. Key messages may include scientific 
findings and should not repeat material already included in the Summary. 
Please note that the Summary and Key Messages of every DRP accepted for publication will appear in 










this reason please ensure that your Summary and Key Messages together provide a comprehensive 
mini-profile of the data resource. 
Data Resource Basics: Brief details of the following information where relevant: Country or area 
covered by the data resource; Units, groups or individuals covered; Survey Type, (e.g. Demographic & 
Health Survey, Malaria Indicator Survey); Data collection dates and number of repeat surveys; Topic 
headings (e.g. diabetes testing, maternal mortality); and Funding sources. Some of this material might 
be best presented in tabular form. 
Data resource area and population coverage: Where relevant, this section should include a map or 
series of maps that indicate the area covered by the data resource and major centres of data collection, 
e.g. hospitals. It must describe the units, groups and individuals from whom data are collected and
describe how contact at each level was achieved and maintained (if relevant).
Survey frequency: The date of the survey and the number of units, groups and/or individuals surveyed 
should be provided. If repeat surveys have been carried out, the dates of each survey should be 
provided together with the numbers surveyed. Where appropriate these details should include numbers 
invited, the response rate and how well the sample represents the population from which it was taken. 
This information can be presented in tabular form. For recent or ongoing repeat surveys include the 
dates when data will be available. 
Measures: The measures collected at each of the different levels included in the data resource, e.g. 
individual, household, group, should be described in as much detail as necessary i.e. methods for
commonly used measures will not need to be described. At least partial presentation in tabular form is 
encouraged. This section should indicate the source (e.g. questionnaire, clinic exam, data linkage), type
of data collected (e.g. biomarker, geographical, genetic, demographic), the methods used to collect the 
data, and the frequency. This section must be sufficiently detailed to provide readers with a clear picture
of the data available
Data Resource use: This section should provide one or two brief illustrative examples of how the data
resource can be used or examples of published work which has used this database. If you are aware of 
any ongoing specific data analysis plans please indicate these here to avoid duplication of effort by
others interested in the data resource. Please also provide an up-to-date citation list for work published
on the data resource.
Strengths and weaknesses: This section should include both the strengths and the limitations of the
data. If the data resource is one of a series e.g. a Key Indicators Survey, please describe any features 
that are unique to the particular data resource or country/area location, if applicable.
Data Resource access: This section should describe how readers can access and download the data. 
The location and format of the data should be described together with variable lists and data
dictionaries, where available. If the data are open access a web address should be provided. If an 
application is required, please indicate where the application form can be found and the process for
submitting an application. Briefly indicate the software required to access the database and/or use the
data, if applicable.
Please avoid using jargon and non-standard abbreviations. 
LANGUAGE EDITING 
Particularly if English is not your first language, before submitting your manuscript you may wish to 
have it edited for language. This is not a mandatory step, but may help to ensure that the academic 
content of your paper is fully understood by journal editors and reviewers. Language editing does not 
guarantee that your manuscript will be accepted for publication. If you would like information about one 
such service please click here. There are other specialist language editing companies that offer similar 
services and you can also use any of these. Authors are liable for all costs associated with such services. 
COPY EDITING 
All accepted manuscripts are subject to copy editing. 
PROOFS 
The first author will receive a pdf proof of the article. Proof correction must not be used as an 
opportunity to revise the paper. Any essential changes should take up the same amount of space if 
possible. Alterations, other than corrections of printer's errors, are expensive and may be charged to 










It is particularly important to read reference lists at the proof stage in case any omissions/errors have 
been found and noted during copy editing. 
The Editors reserve the right to make minor grammatical and other changes at any stage before 
publication. These are sometimes necessary to make the paper conform to the general style of the 
Journal. Proofs not returned to the Editorial Assistant within two weeks of the date of postmark may be 
held over to the next issue. 
OFFPRINTS 
Offprints may be purchased using the Oxford Journals Author Services site. Orders from the UK will be 
subject to a 20% VAT charge. For orders from elsewhere in the EU you or your institution should 
account for VAT by way of a reverse charge. Please provide us with your or your institution’s VAT 
number. 
SUPPLEMENTARY DATA 
Supporting material that is not essential for inclusion in the full text of the manuscript, but would 
nevertheless benefit the reader, can be made available by the publisher as online-only content, linked to 
the online manuscript. The material should not be essential to understanding the conclusions of the 
paper, but should contain data that is additional or complementary and directly relevant to the article 
content. Such information might include more detailed Methods, extended data sets/data analysis, or 
additional figures (including colour). All text and figures must be provided in suitable electronic formats 
(for instructions for the preparation of Supplementary Data please go to here).
All material to be considered as Supplementary Data must be submitted at the same time as the main 
manuscript for peer review. It cannot be altered or replaced after the paper has been accepted for
publication. Please indicate clearly the material intended as Supplementary Data upon submission. Also 
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